New York Blood Center Enterprises

Profile narrative

New York Blood Center Enterprises engages in the collection, processing, and distribution of blood and blood products. The organization supplies whole blood, red blood cells, platelets, plasma, and other components to healthcare providers. In addition to standard blood products, it operates a pharmacy unit, prepares clotting factor concentrates, provides cryopreservation services, performs platelet apheresis (PAT), and conducts clinical apheresis procedures. These specialized services support patients requiring transfusion therapy, coagulation management, and specialized cellular treatments. The organization is organized into multiple operating divisions that oversee donor recruitment, testing, component preparation, and distribution. Blood collection activities are carried out through fixed donor centers and mobile blood drives. All operating divisions were affected to some extent by the ransomware incident reported on January 26, 2025. Following detection of suspicious activity, the organization engaged third‑party cybersecurity experts and notified law enforcement. Containment measures were implemented, and systems have been restored sufficiently for blood collection to resume. While some sites continue to rely on manual processes and inbound telephone services remain disrupted, core services such as pharmacy, clotting factor, cryopreservation, PAT, and clinical apheresis have continued without interruption.

The ransomware incident highlighted the organization's reliance on information technology for administrative and operational coordination. Despite the cyber disruption, essential blood‑related services remained operational, indicating a degree of resilience in critical workflows. The incident prompted engagement of external cybersecurity specialists and coordination with law‑enforcement authorities. New York Blood Center Enterprises continues to monitor its systems and implement measures to prevent recurrence. The organization maintains a commitment to providing safe blood products and specialized therapeutic services to the communities it serves. No explicit details regarding ownership, parent company, or subsidiary structure are disclosed in the available source material. Consequently, any description of its corporate governance beyond its role as a blood center enterprise would be speculative. The focus of the known information remains on its service offerings and response to the cybersecurity event. These facts constitute the currently verifiable profile of New York Blood Center Enterprises based on the provided context. Further details about its scale, geographic reach, or organizational affiliations would require additional authoritative sources.

Incidents

1 incident linked to this organisation.